Daniel Petrylak

3.6k total citations · 1 hit paper
8 papers, 2.4k citations indexed

About

Daniel Petrylak is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Daniel Petrylak has authored 8 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 3 papers in Molecular Biology and 2 papers in Oncology. Recurrent topics in Daniel Petrylak's work include Prostate Cancer Treatment and Research (5 papers), Prostate Cancer Diagnosis and Treatment (3 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Daniel Petrylak is often cited by papers focused on Prostate Cancer Treatment and Research (5 papers), Prostate Cancer Diagnosis and Treatment (3 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Daniel Petrylak collaborates with scholars based in United States and United Kingdom. Daniel Petrylak's co-authors include Alan Yagoda, George Wilding, Susan Halabi, Eric J. Small, William Kevin Kelly, Howard I. Scher, Alison Martin, Ian F. Tannock, Michael J. Morris and Mario A. Eisenberger and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Daniel Petrylak

8 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

2008 1.7k citations Howard I. Scher, Susan Halabi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Petrylak United States	6	1.9k	813	726	592	453	8	2.4k
Mary B. Todd United States	18	2.1k 1.1×	605 0.7×	739 1.0×	691 1.2×	428 0.9×	54	2.5k
Diletta Bianchini United Kingdom	22	1.6k 0.9×	659 0.8×	755 1.0×	768 1.3×	356 0.8×	68	2.1k
David Lorente Spain	28	1.8k 1.0×	1.2k 1.5×	653 0.9×	1.1k 1.8×	594 1.3×	100	2.9k
Ivo Kocák Czechia	13	2.5k 1.3×	1.4k 1.7×	937 1.3×	798 1.3×	724 1.6×	41	3.3k
K.N. Chi Canada	17	1.2k 0.6×	703 0.9×	462 0.6×	405 0.7×	397 0.9×	76	1.6k
John C. Araujo United States	25	1.4k 0.8×	1.1k 1.3×	509 0.7×	567 1.0×	851 1.9×	89	2.5k
Carmel Pezaro United Kingdom	21	1.8k 0.9×	498 0.6×	631 0.9×	792 1.3×	466 1.0×	60	2.2k
Susan Feyerabend United Kingdom	21	3.2k 1.7×	1.0k 1.2×	1.0k 1.4×	1.1k 1.9×	726 1.6×	71	3.9k
Michael T. Schweizer United States	33	2.2k 1.1×	1.1k 1.3×	444 0.6×	746 1.3×	929 2.1×	144	3.1k
Shinta Cheng United States	13	1.3k 0.7×	441 0.5×	537 0.7×	432 0.7×	257 0.6×	39	1.6k

Countries citing papers authored by Daniel Petrylak

Since Specialization

Citations

This map shows the geographic impact of Daniel Petrylak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Petrylak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Petrylak more than expected).

Fields of papers citing papers by Daniel Petrylak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Petrylak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Petrylak. The network helps show where Daniel Petrylak may publish in the future.

Co-authorship network of co-authors of Daniel Petrylak

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Petrylak. A scholar is included among the top collaborators of Daniel Petrylak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Petrylak. Daniel Petrylak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Kelly, William Kevin, Johann S. de Bono, George Blumenschein, et al.. (2009). Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors. Journal of Clinical Oncology. 27(15_suppl). 3531–3531. 9 indexed citations

2.

Scher, Howard I., Susan Halabi, Ian F. Tannock, et al.. (2008). Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology. 26(7). 1148–1159. 1696 indexed citations breakdown →

3.

Molife, R., James Lee, Daniel Petrylak, et al.. (2007). A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 6. 2 indexed citations

4.

Petrylak, Daniel. (2005). Therapeutic options in androgen‐independent prostate cancer: building on docetaxel. British Journal of Urology. 96(s2). 41–46. 41 indexed citations

5.

Rosenbaum, Eli, Adam S. Kibel, Bruce J. Roth, et al.. (2004). Adjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial. Journal of Clinical Oncology. 22(14_suppl). 4649–4649. 2 indexed citations

6.

Small, Eric J., Susan Halabi, Mark J. Ratain, et al.. (2002). Randomized Study of Three Different Doses of Suramin Administered With a Fixed Dosing Schedule in Patients With Advanced Prostate Cancer: Results of Intergroup 0159, Cancer and Leukemia Group B 9480. Journal of Clinical Oncology. 20(16). 3369–3375. 44 indexed citations

7.

Yagoda, Alan & Daniel Petrylak. (1993). Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 71(S3). 1098–1109. 323 indexed citations

8.

Cordon‐Cardo, Carlos, David D. Wartinger, Daniel Petrylak, et al.. (1992). Altered Expression of the Retinoblastoma Gene Product: Prognostic Indicator in Bladder Cancer. JNCI Journal of the National Cancer Institute. 84(16). 1251–1256. 254 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact